HOME >> BIOLOGY >> NEWS
PET accurately identifies esophageal cancer patients' positive responses to chemotherapy

WASHINGTON, D.C.Early metabolic imaging with positron emission tomography (PET) accurately identifies patients responding to chemotherapy for esophageal cancer, noted German researchers at the 54th Annual Meeting of SNM, the world's largest society for molecular imaging and nuclear medicine professionals.

"This is the first study to apply PET results from early metabolic response assessment to clinical decision making in the treatment of common solid tumors," said Ken Herrmann, a resident in the department of nuclear medicine at Technical University in Munich, Germany. "The outcome for metabolic responders turned out to be remarkably favorable compared to metabolic non-responders. Our results show that PET helps select patients who are benefiting from chemotherapy," he noted. "Based on our early response assessment, the course is set for tailoring multimodality treatment on the basis of tumor biology," explained Herrmann.

In addition, PET-response-guided treatment "helped circumvent the administration of inefficient chemotherapy to patients with no metabolic responsewithout compromising their outcome," added Herrmann.

Less well-known than lung cancerbut no less seriousesophageal cancer starts in the inner layer of the esophagus, the 10-inch long tube that connects your throat and stomach. Adenocarcinoma is esophageal cancer that begins in cells that make and release mucus and other fluids. In this country, more than 14,000 persons are expected to die from the disease, and more than 15,000 new cases will be diagnosed this year.

The MUNICON trial, conducted from May 2003 through August 2005, was the first study conducted to apply PET results from early metabolic response assessment to clinical decision-making in the treatment of common solid tumors, said Herrmann. "This clinical trial delineated how response-guided treatment algorithms may be applied to clinical practice, serving as a model for other malignant diseaseslike l
'"/>

Contact: Maryann Verrillo
mverrillo@snm.org
703-652-6773
Society of Nuclear Medicine
3-Jun-2007


Page: 1 2

Related biology news :

1. Fusing imaging technologies creates synergy, helps diagnose heart disease accurately
2. Preterm birth risk quickly and accurately detected with proteomic profiling
3. New research identifies anti-viral protein that may predict who might be at risk to develop lupus
4. U-M team identifies gene that regulates blood-forming fetal stem cells
5. Study identifies new gene therapy tools for inherited blindness
6. Study identifies energy efficiency as reason for evolution of upright walking
7. Study identifies a common genetic risk factor for colorectal and prostate cancer
8. M. D. Anderson team identifies new oncogene for brain cancer
9. Weill Cornell team identifies potential new cancer drug target
10. Study identifies 5 genetic themes key to keeping stem cells in a primitive, flexible state
11. 454 sequencing identifies HIV drug resistance at early stage

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/29/2020)... ... January 29, 2020 , ... ... vitro toxicology testing solutions, has announced a record earnings year for 2019. With ... showed more than a twenty percent increase in revenue and a thirty percent ...
(Date:1/27/2020)... ... ... On Thursday, February 20, 2020 at 10am EST (3pm GMT/UK), join Gary ... Castle, Global Account Manager Medical Device at PRISYM ID for an informative ... deadlines, best practices in creating and submitting product data and best practices in preparing ...
(Date:1/24/2020)... ... , ... Worldwide Business with kathy ireland® has announced an exclusive ... of Sales and Marketing Jeff Maier to discuss their innovative technology, High-Speed Vibration Therapy. ... 26, 2020 at 5:30 p.m. EST and internationally on Bloomberg Television on Saturday, Jan. ...
Breaking Biology News(10 mins):
(Date:1/28/2020)... ... January 28, 2020 , ... ... Assay Kits . The new Salivary Total Human IgG Assay Kit ... immunoglobulin G in saliva, researchers can extend the accuracy and ease of use ...
(Date:1/24/2020)... ... January 24, 2020 , ... The plastic and reconstructive surgeons ... in New Jersey epitomize the notion that plastic surgery is much more than just ... popular media. , Over the last 20 years NJ Top Docs, Dr. Andrew Elkwood, ...
(Date:1/23/2020)... ... January 22, 2020 , ... Ideal ... cosmetic surgery industry at two recent North American investor forums specializing in medical ... Genuity Medical Technologies & Diagnostics Forum on November 21, 2019 in New York ...
(Date:1/22/2020)... ... 21, 2020 , ... COBO Technologies and Cardea Bio partner ... have agreed to co-develop and market a portfolio of CRISPR QC products and ... the longer-term, the parties aim to develop a COBO branded QC device based ...
Breaking Biology Technology:
Cached News: